These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 35074264)

  • 1. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
    J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
    Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Somatically Acquired
    Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
    Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
    Eikesdal HP; Yndestad S; Elzawahry A; Llop-Guevara A; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Vagstad G; Venizelos A; Minsaas L; Leirvaag B; Gudlaugsson EG; Vintermyr OK; Aase HS; Aas T; Balmaña J; Serra V; Janssen EAM; Knappskog S; Lønning PE
    Ann Oncol; 2021 Feb; 32(2):240-249. PubMed ID: 33242536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
    BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
    Wethington SL; Shah PD; Martin L; Tanyi JL; Latif N; Morgan M; Torigian DA; Rodriguez D; Smith SA; Dean E; Domchek SM; Drapkin R; Shih IM; Brown EJ; Hwang WT; Armstrong DK; Gaillard S; Giuntoli R; Simpkins F
    Clin Cancer Res; 2023 Aug; 29(15):2800-2807. PubMed ID: 37097611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.